scholarly article | Q13442814 |
P356 | DOI | 10.1016/J.YGYNO.2011.05.022 |
P698 | PubMed publication ID | 21664657 |
P2093 | author name string | D Scott McMeekin | |
Robert S Mannel | |||
Joan L Walker | |||
Lisa M Landrum | |||
Johnny Hyde | |||
Kathleen N Moore | |||
P2860 | cites work | Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the G | Q33335882 |
Intraperitoneal chemotherapy strategies in the treatment of epithelial ovarian carcinoma | Q33536730 | ||
Relationship between cisplatin administration and the development of ototoxicity | Q34495455 | ||
Ototoxicity after intraperitoneal chemotherapy: a case report | Q36791118 | ||
Intraperitoneal chemotherapy for patients with advanced epithelial ovarian cancer: a review of complications and completion rates | Q36995650 | ||
Outpatient platinum-taxane intraperitoneal chemotherapy regimen for ovarian cancer | Q37613377 | ||
The complex clinical picture of presumably allergic side effects to cytostatic drugs: symptoms, pathomechanism, reexposure, and desensitization | Q37770689 | ||
Paclitaxel delivered as a 3-hr infusion with cisplatin in patients with gynecologic cancers: unexpected incidence of neurotoxicity | Q42554765 | ||
Completion of intraperitoneal chemotherapy in advanced ovarian cancer and catheter-related complications. | Q43230496 | ||
Complications associated with intraperitoneal chemotherapy catheters | Q43558713 | ||
An outpatient intraperitoneal chemotherapy regimen for advanced ovarian cancer | Q44044542 | ||
Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer. | Q50512108 | ||
Intraperitoneal catheter outcomes in a phase III trial of intravenous versus intraperitoneal chemotherapy in optimal stage III ovarian and primary peritoneal cancer: a Gynecologic Oncology Group Study. | Q51301047 | ||
Intraperitoneal chemotherapy for ovarian cancer: 2009 goals. | Q51797268 | ||
Intraperitoneal cisplatin and paclitaxel in ovarian cancer. | Q53263238 | ||
Intraperitoneal chemotherapy: analysis of complications with an implanted subcutaneous port and catheter system | Q70188668 | ||
European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion | Q72880127 | ||
Clinical features of hypersensitivity reactions to carboplatin | Q73181371 | ||
Intraperitoneal chemotherapy in patients with advanced ovarian cancer: the con view | Q81192248 | ||
Evaluation of an intraperitoneal chemotherapy program implemented at the Princess Margaret Hospital for patients with epithelial ovarian carcinoma | Q83170387 | ||
Intraperitoneal therapy for ovarian cancer: why has it not become standard? | Q83917354 | ||
P433 | issue | 3 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | cisplatin | Q412415 |
paclitaxel | Q423762 | ||
uterine tube | Q1233836 | ||
fallopian tube cancer | Q4818922 | ||
fallopian tube carcinoma | Q18554948 | ||
phase II clinical trial | Q42824440 | ||
P304 | page(s) | 527-531 | |
P577 | publication date | 2011-06-12 | |
P1433 | published in | Gynecologic Oncology | Q5625182 |
P1476 | title | Phase II trial of intraperitoneal cisplatin combined with intravenous paclitaxel in patients with ovarian, primary peritoneal and fallopian tube cancer | |
P478 | volume | 122 |
Q90431035 | Evaluation of non-completion of intraperitoneal chemotherapy in patients with advanced epithelial ovarian cancer |
Q44019385 | Increased elimination of paclitaxel by magnesium isoglycyrrhizinate in epithelial ovarian cancer patients treated with paclitaxel plus cisplatin: a pilot clinical study |
Q37735208 | Profound sensorineural hearing loss after one cycle of intraperitoneal cisplatin in treatment of advanced ovarian cancer. |
Search more.